Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


NICE Sends Out Cost Warning By Flatly Rejecting Kadcyla On Price

This article was originally published in The Pink Sheet Daily

Executive Summary

Not inspired by its clinical effectiveness, NICE has said it will not recommend Roche's “over-priced” Kadcyla for breast cancer.


Related Content

Roche Won’t Match NICE's Excessive Discount Expectations For Kadcyla
European Notebook: Price Cuts Planned In France; IPO Window Thrown Open; European Big Pharmas Pursue Major Deals
U.K. Coverage Rejection Of Alimta In NSCLC Increases Concerns About Access To Cancer Drugs
Cancer Drugs Fund Extended As Pharma Calls For U.K. HTA Rethink
Herceptin Less-Frequent Dosing Is Preferred For Early-Stage Breast Cancer, NICE Says


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts